H. pylori - Ace Therapeutics
Development of Gastroretentive Drug Delivery Systems
Online Inquiry

Development of Gastroretentive Drug Delivery Systems

The longer stay of the drug in the stomach can achieve better results in the treatment of H. pylori. Stability and longer residence time allow more drugs (e.g., antibiotics) to penetrate the gastric mucus layer to treat H. pylori. To date, research and development of gastroretentive drug delivery systems (GRDDS) have become more well-established, and several classifications of GRDDS have evolved, including floating, expanding, mucoadhesive, and high-density systems. And antibiotics are thought to be more effective in eradicating H. pylori through absorption from the gastric lumen than through absorption from the blood into the mucus.

Fig. 1 Mucoadhesive GRDDS (Zanke et al., 2022).Fig. 1 Mucoadhesive GRDDS (Zanke et al., 2022).

Ace Therapeutics assists to develop drug delivery systems for the treatment of H. pylori and provides development services for GRDDS. We focus on mucoadhesive drug delivery systems (MDDS) and we offer to develop MDDS by taking advantage of the adhesion properties of H. pylori itself and the adhesion properties of its associated therapeutic drugs. Below are our specific development strategies.

Development of GRDDS based on the adhesins of H. pylori

H. pylori adhesins (e.g., BabA, Horb, and CagL) have natural adhesion to gastric cells, and we utilize these adhesions to provide MDDS. For example, we offer to design and produce proteins similar to the H. pylori BabA adherent fraction, which adheres to blood group antigens, and apply them to nano-coatings. This type of delivery system development service is a key part of our offering for GRDDS development. It not only increases drug residence time but also competitively reduces H. pylori adhesion to the gastric mucosa.

Development of GRDDS based on therapeutic substances targeting H. pylori

We offer services to develop MDDS using substances that are therapeutic for H. pylori infection and are also mucoadhesive. Okra mucilage is a highly viscous polysaccharide that has been shown to have a therapeutic effect on H. pylori. We offer modification of the mucoadhesive polysaccharide of okra and use them in drug delivery systems. This system could better enhance the therapeutic effect of the drug against H. pylori. Similarly, we also provide services for the development of mucoadhesive delivery systems using apple pectin and the high-molecular-weight constituent of cranberry.

Development of GRDDS based on probiotics

We provide probiotic drug delivery system development for H. pylori protein and peptide drugs. We provide edited probiotics that express specific protein and peptide drugs, which are then used to treat H. pylori. This drug delivery system utilizes probiotic reproduction for continuous drug delivery, resulting in a long-lasting therapeutic effect. And our extensive experience in expression and optimization of peptide and protein drugs in different expression systems allows us to provide this service efficiently.

Contact us

Ace Therapeutics, as an H. pylori-focused company, offers GRDDS development for treating H. pylori. Several of these GRDDS (e.g., H. pylori adhesion-based drug development systems) can be used not only for the delivery of H. pylori drugs but also for the delivery of other drugs that require improved gastric residence time. Contact us now to power your GRDDS development.


  1. Mahor, A.; Gupta, R. Recent advances in gastro retentive drug delivery systems and its application on treatment of H. pylori infections. Journal of Analytical & Pharmaceutical Research. 2018, 7(4): 404‒10.
  2. Zanke, A. A.; et al. Recent Advance in Gastroretantive Drug Delivery System (GRDDS). Asian Journal of Pharmaceutical Research. 2022, 12(2): 143-49.

※ All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.